Interleukin-6 level in patients with colorectal cancer

Esfandi, Farideh; Ghobadloo, Shahrokh M.; Basati, Gholam

doi:10.1016/j.canlet.2005.12.003

Cited by 66 publications

(47 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies reported here and by others indicate that IL-6 functions as a double-edged sword, on the one hand promoting T cell-mediated antitumor immunity, while on the other contributing to inflammation-associated tumorigenesis (1,2). These latter observations are consistent with the correlation between high circulating levels of IL-6 and poor prognosis in cancer patients (54,55). In murine models and in human colorectal, breast, and hepatocellular carcinoma, STAT3 activation in tumor cells by IL-6 produced by infiltrating myeloid cells, CD4 + T cells, or cancer cells leads to induction of target genes that promote oncogenic transformation, proliferation (cyclin D1, c-Myc), and survival (bcl-XL, survivin) (56)(57)(58)(59)(60)(61)(62).…”

Section: Discussionsupporting

confidence: 92%

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

Fisher¹,

Chen²,

Skitzki³

et al. 2011

J. Clin. Invest.

213

311

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

Fisher¹,

Chen²,

Skitzki³

et al. 2011

J. Clin. Invest.

213

311

View full text Add to dashboard Cite

“…The association of IL-6 or CRP with survival in cancer patients may either be due to cancer pathology or other comorbidities. It is possible that elevated concentrations of inflammatory markers in people with cancer reflect a more advanced cancer stage at diagnosis or a more aggressive tumor, hence leading to worse prognosis (14). Alternatively, elevated IL-6 or CRP concentrations may indicate other non-cancer comorbidities (15,16) or a cumulative effect of a lifetime of adverse health events (17,18) and may thus be associated with decreased survival irrespective of the presence of cancer or the course of any malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Associations of Circulating C-Reactive Protein and Interleukin-6 with Survival in Women with and without Cancer: Findings from the British Women's Heart and Health Study

Heikkilä

Ebrahim

Rumley

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Inflammation is associated with worse prognosis and survival in many cancers. Our aim was to investigate the associations of circulating C-reactive protein (CRP) and interleukin-6 (IL-6) concentrations with all-cause mortality in cancer patients and to determine whether any associations were specific to malignancy. Method: We used data from the British Women's Heart and Health Study, a cohort of 4,286 women aged 60 to 79 years. We investigated the associations between CRP, IL-6, and survival in women with and without cancer using Cox regression and assessed the interaction between cancer status and these inflammatory markers to determine whether these associations differed according to cancer status. Results: Elevated CRP and IL-6 were associated with decreased survival in women with cancer [unadjusted hazard ratio per doubling of CRP, 1.22, 95% confidence interval (95%

show abstract

“…Over-expression of certain inflammatory cytokines can suppress the erythroid progenitors, impair iron utilization, and reduce erythropoietin (EPO) production. Serum levels of the inflammatory cytokine IL-6 have been reported to be elevated in patients with breast, colorectal, and lung cancers (3,7,14), and to negatively correlate with hemoglobin levels in cancer patients (2,6). Furthermore, Nieken et al re-ported that administration of recombinant human IL-6 as immunotherapy caused anemia in cancer patients (10).…”

mentioning

confidence: 99%

Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells

et al. 2009

View full text Add to dashboard Cite

We established models of cancer-related anemia in mice from subcutaneous inoculation of two IL-6-producing cancer cell lines, human lung cancer cell line LC-06-JCK and murine colon26 clone 5 colon cancer cells. In both models, elevated levels of IL-6 were detected in sera and hemoglobin levels significantly decreased compared with non-tumor-bearing mice. In the LC-06-JCK model, serum albumin levels also decreased with elevated levels of human IL-6 in sera. On the other hand, serum levels of EPO increased, although anemia developed and did not improve. The development of cancer-related anemia was prevented by the administration of a rat anti-mouse IL-6 receptor antibody, MR16-1, in the LC-06-JCK model. It is therefore suggested that IL-6 causes anemia independent of a reduction in EPO levels. Our preclinical models should be useful for exploring new modalities for the treatment of cancer-related anemia.

show abstract

Interleukin-6 level in patients with colorectal cancer

Cited by 66 publications

References 17 publications

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

Associations of Circulating C-Reactive Protein and Interleukin-6 with Survival in Women with and without Cancer: Findings from the British Women's Heart and Health Study

Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells

Contact Info

Product

Resources

About